Literature DB >> 2996649

Thromboxane (TX)A3 and prostaglandin (PG)I3 are formed in man after dietary eicosapentaenoic acid: identification and quantification by capillary gas chromatography-electron impact mass spectrometry.

S Fischer, P C Weber.   

Abstract

The low incidence of myocardial infarction in Greenland Eskimos has been related to their traditional marine diet rich in eicosapentaenoic acid. However, whether dietary eicosapentaenoic acid is indeed transformed in man to antiaggregatory PGI3 and weakly proaggregatory TXA3 has not been clarified. In our studies we ingested either cod liver oil or mackerel both rich in eicosapentaenoic acid. Formation of TXB3, the hydrolysis product of TXA3, in platelet-rich plasma stimulated ex vivo with collagen was traced by capillary GC/EIMS. Via external standard, TXB3 formation in platelets was estimated to be 5-15% of TXB2 formation. From urine we extracted dinor metabolites of PGI according to a selective method. We utilized delta 17-2,3-dinor-6-keto-PGF1 alpha (PGI3-M) as an index of total body production of PGI3 in analogy to 2,3-dinor-6-keto-PGF1 alpha (PGI2-M), the major urinary metabolite of PGI2. We separated PGI2-M and PGI3-M as the Me, MO, Me3Si derivatives by capillary gas chromatography and identified PGI3-M by EI mass spectrometry. Excretion of PGI3-M, which was not detectable under control conditions, was 83 +/- 25 ng/24 h (SD) after ingestion of cod liver oil and 134 +/- 38 ng/24 h after mackerel ingestion, while excretion of PGI2-M was 162 +/- 52 ng/24 h and 236 +/- 32 ng/24 h, respectively. Our findings with diets rich in EPA show that it is possible in man to change in vivo the spectrum of biologically active prostanoids by nutritional means and alter it in a favourable direction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996649     DOI: 10.1002/bms.1200120905

Source DB:  PubMed          Journal:  Biomed Mass Spectrom        ISSN: 0306-042X


  9 in total

Review 1.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

Authors:  William L Smith; Yoshihiro Urade; Per-Johan Jakobsson
Journal:  Chem Rev       Date:  2011-09-27       Impact factor: 60.622

2.  Fish oil, enriched with polyunsaturated fatty acids of the omega-3-type accelerates the nucleation time in healthy subjects.

Authors:  P Janowitz; W Swobodnik; J G Wechsler; A Janowitz; D Saal; H Ditschuneit
Journal:  Klin Wochenschr       Date:  1991-05-03

Review 3.  Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.

Authors:  Jennifer Yeung; Wenjie Li; Michael Holinstat
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 4.  The expansive role of oxylipins on platelet biology.

Authors:  Jennifer Yeung; Megan Hawley; Michael Holinstat
Journal:  J Mol Med (Berl)       Date:  2017-05-20       Impact factor: 4.599

5.  The effect of dietary enrichment with fish-oil on urinary excretion of N-acetyl-beta-D-glucosaminidase and renal function in proteinuric patients with primary glomerulopathies.

Authors:  J Manitius; B Sulikowska; J Fox; Z Jakubowski; E Ludwiczak; W Lysiak-Szydłowska; B Rutkowski
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

6.  Effect of fish oil supplementation on the excretion of the major metabolite of prostaglandin E in healthy male subjects.

Authors:  A Ferretti; J T Judd; R Ballard-Barbash; P P Nair; P R Taylor; B A Clevidence
Journal:  Lipids       Date:  1991-07       Impact factor: 1.880

7.  Modulating influence of dietary lipid intake on the prostaglandin system in adult men.

Authors:  A Ferretti; J T Judd; P R Taylor; A Schatzkin; C Brown
Journal:  Lipids       Date:  1989-05       Impact factor: 1.880

8.  Mass spectrometric analysis of oxidized eicosapentaenoic Acid sodium salt.

Authors:  Kelsey D Jordan; Rita K Upmacis
Journal:  Lipid Insights       Date:  2013-05-06

Review 9.  Eicosanoids in inflammation in the blood and the vessel.

Authors:  Adriana Yamaguchi; Eliana Botta; Michael Holinstat
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.